James V. Caruso plans to begin marketing a drug named Folotyn in January for T-cell lymphoma, a rare and usually aggressive blood cancer for which he claims patients have “no options.”
A one month treatment using Folotyn costs: $30,000, according to the New York Times (NYT), which Caruso says is “fairly priced,” and “benchmarked” against other drugs marketed for cancer, which also run into the thousands.
